You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 55 No. 3, March 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Psychiatry, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Hormonal and Subjective Responses to Intravenous m-Chlorophenylpiperazine in Women With Seasonal Affective Disorder

Robert D. Levitan, MD; Allan S. Kaplan, MD; Gregory M. Brown, MD, PhD; Franco J. Vaccarino, PhD; Sidney H. Kennedy, MD; Anthony J. Levitt, MD; Russell T. Joffe, MD

Arch Gen Psychiatry. 1998;55:244-249.

Background  There is emerging evidence of serotonergic dysfunction in patients with seasonal affective disorder (SAD). We examined central serotonergic function in female patients with SAD (fall-winter pattern) by means of neuroendocrine and subjective responses to the postsynaptic serotonin receptor agonist m-chlorophenylpiperazine.

Methods  Using a double-blind, randomized, placebo-controlled design, we assessed neuroendocrine and subjective responses to m-chlorophenylpiperazine (0.1 mg/kg intravenously) and placebo in 14 unmedicated female patients with SAD in the depressed state and 15 female normal controls. All testing was done in the fall-winter months and during the follicular phase of the menstrual cycle. Plasma prolactin and cortisol levels were used as neuroendocrine measures, while subjective responses were assessed by means of visual analog scales of 10 mood states.

Results  On the basis of net responses to m-chlorophenylpiperazine (placebo effects subtracted from drug effects), patients with SAD exhibited blunted prolactin responses and less sadness than normal controls in response to the drug. When order of presentation of drug and placebo was taken into consideration, altered "calm" and "high" responses were also found in the patient group.

Conclusion  Evidence of dysfunction at or downstream to central serotonergic receptors in female patients with SAD confirms and extends findings from previous research.


From the Clarke Institute of Psychiatry (Drs Levitan, Brown, Vaccarino, Kennedy, Levitt, and Joffe) and The Toronto Hospital (Dr Kaplan), Department of Psychiatry, University of Toronto, Toronto, Ontario. Dr Levitt is now with the Mood Disorders Clinic, Sunnybrook Hospital, Department of Psychiatry, University of Toronto. Dr Joffe is now with the Departments of Medicine and Psychiatry, McMaster University, Hamilton, Ontario.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.